[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 518
Citations 0
Lab Reports
January 6, 2015

Structural Analysis of Antibodies in Ebola Treatment

JAMA. 2015;313(1):20. doi:10.1001/jama.2014.16897

The experimental Ebola treatment ZMapp, administered to several infected individuals during the ongoing epidemic, contains key components of 2 antibody mixtures (MB-003 and ZMab) whose mechanisms of action have remained unclear. Through the use of single-particle electron microscopy, Scripps Research Institute investigators and their colleagues have determined the structure of each antibody in ZMapp, as well as additional antibodies from MB-003 and ZMab cocktails from which ZMapp was derived, bound to the Ebola virus surface glycoprotein (Murin CD et al. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1414164111 [published online November 17, 2014]).

First Page Preview View Large
First page PDF preview
First page PDF preview